Emster Kurt von - 02 Jun 2021 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: Director
Issuer ticker: PCVX
Reported as of: 02 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2021, 19:44:09 UTC
Prior SEC filing: 18 May 2021
Next SEC filing: 01 Oct 2021
Source filing: View source filing
Reporting owner signature: /s/ John Heard, as attorney-in-fact

Key filing fact

Emster Kurt von filed Form 4 for Vaxcyte, Inc. (PCVX) on 03 Jun 2021.

Key facts

This page summarizes Emster Kurt von's Form 4 filing for Vaxcyte, Inc. (PCVX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2021, 19:44.

Change

Previous filing in this sequence was filed on 18 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 02 Jun 2021
Ownership: Direct
Underlying class: Common Stock, $0.001 par value per share
Underlying amount: 15,000
Exercise price: $21.49
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

Footnote F2

The Reporting Person is a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP.

Footnote F3

ABV VI may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.